GlassScriptPhysician profile
Birendra K Trivedi
NPI 1992750244
$14,011.09
in general payments reported to CMS, 2019-2025
61 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $911 · 2021: $1,702 · 2022: $2,563 · 2023: $2,390 · 2024: $2,410 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,039 · Education: $96.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,038.98 |
| Education | $96.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,313.31 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,179.24 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,053.31 | 2019-2024 | Austedo, Ajovy, Austedo Xr |
| Biogen, INC. | $1,037.96 | 2019-2025 | Vumerity, Plegridy |
| Eisai INC. | $986.39 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $945.12 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $726.22 | 2019-2025 | |
| Lundbeck LLC | $573.01 | 2020-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $537.04 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $479.69 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $460.62 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $404.96 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $319.79 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Supernus Pharmaceuticals, INC. | $292.29 | 2019-2022 | |
| Pfizer INC. | $268.76 | 2023-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birendra Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.